Could a tiny device free people with type 1 diabetes from daily shots?

NCT ID NCT06408311

Ongoing Disease control Sponsor: Encellin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a small device placed under the skin that contains insulin-producing cells. The goal is to see if it is safe and tolerable for people with type 1 diabetes who already receive standard islet transplants. Only 10 participants are enrolled, and the main focus is on safety, not yet on how well it controls blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: macro-encapsulated human primary islets
What this could lead to: If successful, this could lead to a safer way to transplant insulin-producing cells without lifelong immune suppression, potentially improving blood sugar control.
What could go wrong: This is a very early Phase 1 trial with only 10 participants, so safety and feasibility are the main goals. The device may not work as hoped, and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

McGill University Health Centre

Montreal, Quebec, H4A 3J1, Canada
UHN

Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.